You are here: Welcome » UNITAID


UNITAID was created in 2006 as part of the global response to HIV/AIDS,Tuberculosis and Malaria by the governments of Brazil, Chile, France, Norwayand the United Kingdom as the “International Drug Purchasing Facility.”

Today it is backed by an expanding “North-South” membership, including Cyprus, Korea, Luxembourg, Spain and the Bill & Melinda Gates Foundation alongside Cameroon, Congo, Guinea, Madagascar, Mali, Mauritius and Niger.

Civil society groups also govern UNITAID, giving a voice to non-governmental organizations and communities living with HIV, malaria and tuberculosis. UNITAID is part of the Global Response to bring new, better, faster and more affordable medicines and technologies to those in need.

UNITAID Uses Innovative Financing to solve market inefficiencies such as gaps in the price, quality, availability, acceptability and/or delivery of health products. Through innovative financing UNITAID attempts to meet these needs and contribute to the global response to bring new, better, faster and more affordable medicines and technologies and systems to those in need. * UNITAID has raised over half of its funds in the last five years through the 'air ticket levy *

Nine countries have implemented the air ticket levy: Cameroon, Chile, Congo, France, Madagascar, Mali, Mauritius, Niger and the Republic of Korea. Norway allocates part of its tax on CO2 emissions. The air ticket levy promotes South– South cooperation by allowing new actors from Africa and Latin America to participate in financing international development. 1)

Timeline shows Gates Foundation alliance in 1999 then GAVI and slowly a global “health” empire emerged.

Abpit Us

Unitaid is an international organisation that invests in new ways to prevent, diagnose and treat HIV/AIDS, tuberculosis and malaria more quickly, more cheaply and more effectively. Unitaid is a hosted partnership of the World Health Organization (WHO).

Unitaid researches and identifies new health solutions with potential to alleviate the burden of HIV/AIDS, tuberculosis and malaria.

Through calls for proposals, Unitaid finds partners best qualified to put key innovations into practice.

These partners receive grants from Unitaid to fast-track access and reduce costs of more effective medicines, technologies and systems.

In this way, Unitaid’s investments establish the viability of health innovations, allowing partner organisations to make them widely available.

Since its establishment in 2006, Unitaid has received over US $2.5 billion in contributions from donors. Unitaid’s main donors are France, the United Kingdom, Norway, the Bill & Melinda Gates Foundation, Brazil, Spain, the Republic of Korea, and Chile.

A key source of income is innovative financing, specifically the solidarity levy on airline tickets implemented by France, which was later adopted by a number of other countries (including Cameroon, Chile, Congo, Guinea, Madagascar, Mali, Mauritius, Niger, and the Republic of Korea).2)

Interesting a “health” org has insecticide development goals complimenting Gates gmo chemical investments.

TB Testing in Africa

Given that TB is the leading cause of death among people living with HIV in Africa, greater access to the test will significantly boost the capacity of healthcare workers to reduce transmission of and premature deaths from the disease. The incremental scaling of the test in high-burden countries could enable the rapid diagnosis of seven hundred thousand cases of TB and save health systems more than $18 million in direct health costs.

“We are pleased to be working with the Bill & Melinda Gates Foundation, PEPFAR, USAID, and UNITAID to make our innovative Xpert MTB/RIF test available for patient management in 145 HBDCs at less than $10 per test,” said Cepheid CEO John Bishop. “As a result, every investment in GeneXpert technology in [HBDCs] will go further to identify patients with tuberculosis or drug-resistant tuberculosis, the first critical step in reducing the shocking mortality rates associated with this deadly disease.”3)

Pandemic Corruption

Highwire - March 3, 2022 Del Bigtree sits down for a one-on-one with the former W.H.O. consultant & research scientist, Tess Lawrie MD, PhD, who was a critical part of the Ivermectin trials over a year ago with overwhelmingly positive conclusions. See data and recorded personal zoom calls that reveal how a key review was attacked from within, keeping the safe, life-saving drug out of the hands of millions of dying Covid patients for more than a year.

Tess outlining UNITAID role derailing Ivermectin from 29 min. andconversations with Andrew Hill4)

Andrew Hill's Ivermectin Problem

Researcher Andrew Hill’s conflict: A $40 million Gates Foundation grant vs a half million human lives Investigative Editor December 9, 2021

by WorldTribune Staff, December 9, 2021

In a stunning admission, virologist Dr. Andrew Hill acknowledged in a zoom call that publication of his study could lead to the deaths of at least a half million people.

In defending his reversal on the effectiveness of ivermectin as a treatment for COVID-19, he discussed his “difficult situation” and said, “I’ve got this role where I’m supposed to produce this paper and we’re in a very difficult, delicate balance.”

The incident is recounted in Robert Kennedy Jr’s New York Times Bestseller, The Real Anthony Fauci: Bill Gates, Big Pharma, and the global war on Democracy and Public Health.

Andrew Hill, PhD, is a senior visiting Research Fellow in Pharmacology at Liverpool University. He is also an advisor for the Bill and Melinda Gates Foundation and the Clinton Foundation. As a researcher for the WHO evaluating ivermectin, Hill wielded enormous influence over international guidance for the drug’s use.

Hill had previously authored a analysis of ivermectin as a treatment for COVID-19 that found the drug overwhelmingly effective.

On Jan. 6 of 2021, Hill testified enthusiastically before the NIH COVID-19 Treatment Guidlelines Panel in support of ivermectin’s use. Within a month, however, Hill found himself in what he describes as a “tricky situation.” Under pressure from his funding sponsors, Hill then published an unfavorable study. Ironically, he used the same sources as in the original study. Only the conclusions had changed.

Shortly before he published, Dr. Tess Lawrie, Director of the Evidence-based Medicine Consultancy in Bath, England, and one of the world’s leading medical research analysts, contacted Hill via Zoom and recorded the call (transcript below). Lawrie had learned of his new position and reached out to try to rectify the situation.

In a remarkable exchange, a transcript of which appears on pages 137 – 143 in Kennedy’s book, Hill admitted his manipulated study would likely delay the uptake of ivermectin in the UK and United States, but said he hoped his doing so would only set the lifesaving drug’s acceptance back by about “six weeks,” after which he was willing to give his support for its use.5)6)

Back to top